Experimental and clinical studies have shown that aldosterone/mineralocorticoid receptor (MR) activation has deleterious effects in the cardiovascular system; however, the signalling pathways involved in the pathophysiological effects of aldosterone/MR in vivo are not fully understood. Several in vitro studies suggest that Epidermal Growth Factor Receptor (EGFR) plays a role in the cardiovascular effects of aldosterone. This hypothesis remains to be demonstrated in vivo. To investigate this question, we analyzed the molecular and functional consequences of aldosterone exposure in a transgenic mouse model with constitutive cardiomyocyte-specific overexpression of a mutant EGFR acting as a dominant negative protein (DN-EGFR). As previously reported, Angiotensin II-mediated cardiac remodelling was prevented in DN-EGFR mice. However, when chronic MR activation was induced by aldosterone-salt-uninephrectomy, cardiac hypertrophy was similar between control littermates and DN-EGFR. In the same way, mRNA expression of markers of cardiac remodelling such as ANF, BNF or β-Myosin Heavy Chain as well as Collagen 1a and 3a was similarly induced in DN-EGFR mice and their CT littermates. Our findings confirm the role of EGFR in AngII mediated cardiac hypertrophy, and highlight that EGFR is not involved in vivo in the damaging effects of aldosterone on cardiac function and remodelling.
References
[1]
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709–717.
[2]
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309–1321.
[3]
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, et al. (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364: 11–21.
[4]
Funder JW (2007) The role of aldosterone and mineralocorticoid receptors in cardiovascular disease. Am J Cardiovasc Drugs 7: 151–157.
[5]
Gekle M, Grossmann C (2009) Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly? Pflugers Arch 458: 231–246.
[6]
Grossmann C, Krug AW, Freudinger R, Mildenberger S, Voelker K, et al. (2007) Aldosterone-induced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter. Am J Physiol Endocrinol Metab 292: E1790–1800.
[7]
Florian JA, Dorrance A, Webb RC, Watts SW (2001) Mineralocorticoids upregulate arterial contraction to epidermal growth factor. Am J Physiol Regul Integr Comp Physiol 281: R878–886.
[8]
Griol-Charhbili V, Fassot C, Messaoudi S, Perret C, Agrapart V, et al. (2011) Epidermal growth factor receptor mediates the vascular dysfunction but not the remodeling induced by aldosterone/salt. Hypertension 57: 238–244.
[9]
Zhai P, Galeotti J, Liu J, Holle E, Yu X, et al. (2006) An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy. Circ Res 99: 528–536.
[10]
Di Zhang A, Cat AN, Soukaseum C, Escoubet B, Cherfa A, et al. (2008) Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling. Hypertension 52: 1060–1067.
[11]
Robert V, Van Thiem N, Cheav SL, Mouas C, Swynghedauw B, et al. (1994) Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension 24: 30–36.
[12]
Sibilia M, Wagner EF (1995) Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 269: 234–238.
[13]
Barrick CJ, Yu M, Chao HH, Threadgill DW (2008) Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice. Toxicol Appl Pharmacol 228: 315–325.
[14]
Zahorowska B, Crowe PJ, Yang JL (2009) Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs. J Cancer Res Clin Oncol 135: 1137–1148.
[15]
de Azambuja E, Bedard PL, Suter T, Piccart-Gebhart M (2009) Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? Target Oncol 4: 77–88.
[16]
Grossmann C, Benesic A, Krug AW, Freudinger R, Mildenberger S, et al. (2005) Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol Endocrinol 19: 1697–1710.
[17]
Gekle M, Freudinger R, Mildenberger S, Schenk K, Marschitz I, et al. (2001) Rapid activation of Na+/H+-exchange in MDCK cells by aldosterone involves MAP-kinase ERK1/2. Pflugers Arch 441: 781–786.
[18]
McEneaney V, Harvey BJ, Thomas W (2007) Aldosterone rapidly activates protein kinase D via a mineralocorticoid receptor/EGFR trans-activation pathway in the M1 kidney CCD cell line. J Steroid Biochem Mol Biol 107: 180–190.
[19]
Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, et al. (2004) Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 109: 2792–2800.
[20]
Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, et al. (2005) Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 97: 434–442.
[21]
Sugiyama T, Yoshimoto T, Tsuchiya K, Gochou N, Hirono Y, et al. (2005) Aldosterone induces angiotensin converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial cells. Endocrinology 146: 3900–3906.
[22]
Grossmann C, Freudinger R, Mildenberger S, Krug AW, Gekle M (2004) Evidence for epidermal growth factor receptor as negative-feedback control in aldosterone-induced Na+ reabsorption. Am J Physiol Renal Physiol 286: F1226–1231.
Schreier B, Rabe S, Schneider B, Ruhs S, Grossmann C, et al. (2011) Aldosterone/NaCl-induced renal and cardiac fibrosis is modulated by TGF-beta responsiveness of T cells. Hypertens Res 34: 623–629.
[25]
Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, et al. (2002) Aldosterone induces a vascular inflammatory phenotype in the rat heart. American journal of physiology Heart and circulatory physiology 283: H1802–1810.
[26]
Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, et al. (1999) Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 33: 981–986.
[27]
Iglarz M, Touyz RM, Viel EC, Amiri F, Schiffrin EL (2004) Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the renin-angiotension system. Am J Hypertens 17: 597–603.
